BP707T · B.Pharm Semester VII · Theory Notes

Regulatory Affairs

Unit V — Clinical Trials, Ethics and Post-Marketing Surveillance (6 hours)

Unit V (6 hours)

Pills & Python Notes

From-zero teaching standard: every technical term is defined before use.

Syllabus coverage: Unit V (6 hours).

PILLS & PYTHON

Pharmacy • Data • AI • Healthcare

Instagram @pillsandpython · pillsandpython.com · YouTube @PillsAndPython

CHAPTER 11: Global Registration of Indian Drug Products and Post-Approval Changes

Learning Objectives

By the end of this chapter, you will be able to:

1 Explain what "global registration" of a drug product means.

2 Describe the general procedure for registering Indian drug products in overseas (foreign) markets.

3 Explain why Indian companies register products abroad and what they must prepare.

4 Define "post-approval change" and explain why changes happen after approval.

5 Classify post-approval changes to NDA and ANDA by their risk/impact level.

6 Explain the concepts of supplements and notifications for reporting changes.

7 Describe the general flow of handling a post-approval change, from idea to implementation.

Definitions

- **Global registration:** The process of getting a drug product approved for sale in foreign (overseas) countries — one country at a time, following each country's own rules. "Global" here means "in world markets outside India."
- **Overseas market:** Any country's medicine market outside India (for example, the United States, Europe, or ASEAN countries, from an Indian company's point of view).
- **Marketing authorization:** The official permission from a country's drug authority to sell a medicine in that country (same idea as "approval").
- **Post-approval change:** Any change a company wants to make to an already-approved drug product or its manufacturing — for example, changing the API supplier, changing the tablet's shape, shifting production to a new factory, or updating the label. "Post-approval" means "after the NDA/ANDA was already approved."
- **Supplement:** A formal submission sent to the regulatory authority asking for approval of (or informing about) a post-approval change to an NDA or ANDA. Think of it as an "addition" to the original application file.
- **Notification (annual report / minor-change reporting):** A simpler way of informing the authority about very small, low-risk changes — sometimes just listed in a periodic report instead of asking advance permission. (Exact reporting categories and names vary by authority — as per the latest guidelines, confirm the current edition.)
- **Change control:** The company's internal system for proposing, reviewing, approving, and documenting any change to a product or process before it is made.
- **Comparability / equivalence after change:** The proof that the product made after the change is still the same safe, effective, quality product as the approved one.

Terminology Table

Term	What It Means in Simple Words
Global registration	Getting your medicine approved for sale in foreign countries
Overseas market	A foreign country's medicine market
Marketing authorization	Official "you may sell here" permission from a country's authority
Dossier	The organized file of documents submitted for registration (often in CTD format)
Post-approval change	Any change to an already-approved product or its manufacture
Supplement	A formal "addition" filing asking about / reporting a change to an NDA or ANDA
Notification	Simply informing the authority about a very small change
Change control	The company's internal rule-book for managing changes safely
GMP (Good Manufacturing Practices)	The quality rules factories must follow while making medicines
Reference authority	A well-known strict drug authority whose approval is respected (e.g., US FDA, EMA)

Simple Explanations

Technical concept → simple explanation → example:

- **Technical concept:** Registration of Indian drug products in overseas markets requires submission of a country-specific dossier demonstrating quality, safety, and efficacy as per the importing country's regulations.
- **Simple explanation:** If an Indian company wants to sell its tablet in another country, it must ask that country's drug authority for permission, giving documents that prove the tablet is well-made, safe, and works. Each country has its own forms and rules, so the company prepares the dossier accordingly (usually in CTD format, studied in Chapter 10).
- **Example:** An Indian company making metformin tablets wants to sell them in an ASEAN country. It prepares an ACTD-format dossier, submits it to that country's authority, answers their questions, and gets marketing authorization.

General procedure for registering an Indian drug product overseas (step by step):

1. **Select the target country/market:** Study that country's rules, which authority to apply to, and what dossier format is expected (CTD/eCTD/ACTD or national format) — as per the latest guidelines of that country.
2. **Check product eligibility:** Confirm the product type (generic vs new drug), patent/protection status of the innovator, and whether local rules allow it.
3. **Prepare the dossier:** Compile quality (Module 3), nonclinical, and clinical data as required; arrange in the country's accepted format; prepare country-specific Module 1 (forms, labelling in local language if required).

4 **Appoint a local agent (if required):** Many countries require a local representative or agent to file and communicate on the company's behalf — as per that country's rules.

5 **Submit the application:** File the dossier with the country's drug authority and pay the prescribed fee (as per the latest fee notification — confirm the current edition).

6 **Respond to queries:** The authority reviews and asks questions ("deficiency letter"/queries); the company replies with data or clarifications.

7 **Inspection (if applicable):** The authority may inspect the Indian manufacturing plant for GMP compliance before approval.

8 **Approval / marketing authorization:** The authority grants permission; the product can now be sold in that country, subject to local labelling, import, and post-marketing rules.

What are post-approval changes? (simple explanation)

After a drug is approved, life goes on: a company may want a cheaper API supplier, a bigger factory, a better tablet coating, or a label update with new safety information. But the approval was given for the EXACT product and process described in the NDA/ANDA. So the company cannot just change things silently — it must tell the authority, and for important changes, get permission BEFORE making the change.

Classification of post-approval changes (by risk):

Regulatory systems classify changes by how much they could affect the product's quality, safety, or effectiveness:

1 **Major changes (high risk):** Changes that could significantly affect the product — for example, changing the manufacturing process in an important way, changing the API supplier to one with a different process, or changing the formulation. These need prior approval through a supplement BEFORE the change is made.

2 **Moderate changes (medium risk):** Changes with a moderate chance of affecting the product — for example, certain changes in manufacturing site or process within approved ranges. These are reported through a supplement/notification system as per the authority's rules — some need approval before implementation, others can be reported within a defined time.

3 **Minor changes (low risk):** Tiny changes with almost no risk — for example, small editorial label corrections or minor administrative updates. These are usually just notified to the authority, sometimes in a periodic/annual report.

(The exact names, categories, and timelines of these reporting classes differ between authorities such as US FDA, EMA, and others — always follow the latest guidelines of the concerned authority and confirm the current edition.)

Supplements vs notifications — the concept:

- **Supplement:** A formal filing added to the original NDA/ANDA, used for changes that need the authority's review — and for major changes, its APPROVAL — before the change is put into practice.
- **Notification:** A simpler information-only route for low-risk changes — the company informs the authority (sometimes in a routine periodic report) without waiting for advance permission.

Simple rule of thumb: Bigger risk → bigger paperwork and earlier permission. Smaller risk → simple information.

Classifications

Classification 1 — Registration pathways for Indian products abroad (by product type):

1. **Generic registration route:** For copies of approved innovator drugs — dossier shows sameness + bioequivalence (ANDA-type logic).
2. **New drug registration route:** For new active ingredients or new combinations — dossier shows full safety and effectiveness data (NDA-type logic).

Classification 2 — Post-approval changes by what is being changed:

1. **Changes in manufacturing (CMC changes):** New API supplier, new manufacturing site, new equipment, changed process steps, changed batch size.
2. **Changes in the product itself:** Changed formulation, changed strength, changed container/packaging.
3. **Changes in labelling:** New safety warnings, new indications, updated patient leaflet.
4. **Administrative changes:** Company name change, address change, minor paperwork updates.

Classification 3 — Post-approval changes by risk level (reporting route):

1. **Major (high risk) → prior-approval supplement:** Permission needed BEFORE making the change.
2. **Moderate (medium risk) → supplement/notification as per rules:** Reported through the defined channel; some need approval first, others are notified within set timelines.
3. **Minor (low risk) → notification/periodic report:** Simply informed to the authority, often in a routine report.

Mechanisms / Processes

Process 1 — General overseas registration flow (mechanism):

```
INDIAN COMPANY
      │
      ▼
1. Choose country → study its rules & dossier format
      │
      ▼
2. Prepare dossier (CTD/eCTD/ACTD; Module 1 country-specific)
      │
      ▼
3. Appoint local agent (if the country requires)
      │
      ▼
4. Submit application + fee to the country's authority
      │
      ▼
5. Authority reviews → sends queries
      │
      ▼
6. Company answers queries (may go back and forth)
      │
      ▼
7. GMP inspection of Indian plant (if required)
      │
      ▼
8. MARKETING AUTHORIZATION → product can be sold there
```

Process 2 — Handling a post-approval change (mechanism from idea to implementation):

1 **Idea:** Someone proposes a change (e.g., "let's shift tablet coating to a cheaper supplier").

2 **Internal change control:** The company's quality team assesses the change's risk and plans what testing is needed (e.g., stability studies, comparative dissolution).

3 **Classify the change:** Major, moderate, or minor — based on its potential impact on quality/safety/effectiveness, as per the authority's classification.

4 **Generate supporting data:** Run the needed studies to prove the changed product is still equivalent and stable.

5 **File with the authority:** Submit a prior-approval supplement (major), the defined supplement/notification (moderate), or a notification/periodic report entry (minor).

6 **Wait or proceed per rules:** For major changes — wait for approval before implementing. For lower-risk changes — follow the authority's defined reporting route.

7 **Implement and document:** Make the change, record everything, and continue routine quality monitoring.

Process 3 — Why the risk-based system works (the logic):

The authority cannot re-examine every tiny change with full review — that would freeze industry. So it applies a simple principle: **the bigger the possible harm, the stricter the control.** A new factory (big risk) gets full review before approval; a spelling correction on a label (tiny risk) just gets notified. This keeps patients safe without blocking normal business improvements.

Textual Diagrams / Flowcharts

Diagram 1 — Overseas registration journey of an Indian product:




Diagram 2 — Post-approval change decision tree:





Diagram 3 — Life cycle of an approved product:



Key takeaway from the diagrams: Selling abroad = study the country's rules → build the dossier → submit → answer queries → get marketing authorization. After approval, every change is risk-classified: major = ask permission first (supplement), minor = just inform (notification).

Infographic Concept Box

INFOGRAPHIC CONCEPT: A world map with an Indian factory on the left and three destination countries on the right, connected by dotted shipping routes. Each route ends at a "customs gate" shaped like a document folder labeled with the dossier format for that region (CTD / eCTD / ACTD). Below the map, a three-level traffic-light panel for post-approval changes: RED light = "Major change — STOP, get supplement approval first"; YELLOW light = "Moderate change — CAUTION, follow the defined supplement/notification route"; GREEN light = "Minor change — GO, just notify the authority." Icons: factory, cargo ship, document folders, traffic lights. Colors: saffron/green accents for the Indian origin, blue for the routes, red-yellow-green for the change panel.

Tables

Table 1 — Steps of overseas registration (summary):

Step	What Happens	Key Output
1. Market selection	Study the target country's authority, rules, dossier format	Registration strategy
2. Eligibility check	Patent/protection status, product type (generic vs new)	Go / no-go decision
3. Dossier preparation	Compile quality, safety, efficacy data in CTD/eCTD/ACTD; country-specific Module 1	Complete dossier
4. Local agent	Appoint a local representative if the country requires	Authorized agent
5. Submission	File application + fee with the foreign authority	Application under review
6. Query response	Answer the authority's questions with data	Resolved queries
7. Inspection	GMP inspection of the Indian plant, if required	Inspection outcome
8. Authorization	Marketing authorization granted	Product can be sold there

Table 2 — Post-approval change classification:

Risk Level	Meaning	Example	Reporting Route (concept)
Major (high)	Could significantly affect quality, safety, or effectiveness	Change of API manufacturing process; new manufacturing site with major differences	Prior-approval supplement — permission needed BEFORE the change
Moderate (medium)	Moderate potential impact	Certain site or process changes within defined conditions	Defined supplement/notification route per the authority's rules
Minor (low)	Minimal or no impact expected	Editorial label correction; minor administrative update	Notification — inform the authority, often in a periodic report

(Exact category names, examples, and timelines are defined by each authority's own guidelines — always confirm the current edition for the market concerned.)

Table 3 — Supplement vs notification:

Feature	Supplement	Notification
What it is	A formal "addition" filing to the NDA/ANDA	A simpler information to the authority
Used for	Changes needing review (and for major changes, prior approval)	Very low-risk changes
Timing	Filed when the change is proposed (major: before implementing)	Reported as defined by the authority, sometimes in periodic reports
Authority action	Reviews and (for major) approves	Records the information

Examples

1. **Overseas registration example:** An Indian company makes amoxicillin capsules. To sell them in an ASEAN country, it prepares an ACTD dossier, appoints a local agent there, submits the application, answers the authority's queries on stability data, passes a GMP inspection of its Indian plant, and receives marketing authorization.
2. **Generic vs new drug abroad:** The same Indian company registers a copy of an off-patent drug through the generic route (showing bioequivalence) in one country, and a new fixed-dose combination through the new-drug route (full data) in another.
3. **Major change example:** The company wants to shift API sourcing to a new supplier whose manufacturing process is different. This is a major change — it files a prior-approval supplement with comparative data and waits for approval before using the new supplier's API.
4. **Minor change example:** The company corrects a spelling mistake in the patient leaflet. This is a minor change — it notifies the authority through the defined simple route.
5. **Label change example:** New safety information about a side effect must be added to the label. The company files the appropriate supplement/notification for the labelling change as per the authority's rules, so doctors and patients get updated information.

Analogies

1. **Overseas registration = visa application:** To visit a foreign country you need a visa — each country has its own form, fee, and interview. To sell a medicine in a foreign country you need marketing authorization — each country's authority has its own dossier format, fee, and review questions.
2. **Post-approval changes = house renovation after occupancy certificate:** Once your house is approved and you are living in it, you can repaint a wall freely (minor — just inform the society), but breaking down a load-bearing wall needs prior written permission (major — supplement approval first).
3. **Traffic-light analogy:** Major change = red light (stop, get permission first). Moderate change = yellow light (proceed carefully through the defined route). Minor change = green light (go, just inform).
4. **Supplement = addendum to a contract:** When a signed contract needs an important change, both parties sign an addendum. When an approved NDA/ANDA needs an important change, the company files a supplement — an addendum to the original approval.

Pharmacy Relevance

- Pharmacists in regulatory affairs departments of Indian export-oriented companies spend their careers on exactly this: preparing overseas dossiers and managing post-approval change filings — this chapter describes real daily RA work.
- Pharmacists in production and quality assurance initiate most post-approval changes (new supplier, new equipment, process improvements) and must understand that no change is "free" — each must go through change control and the correct regulatory route.
- As a community or hospital pharmacist, you see the results: when a tablet's appearance, pack, or leaflet changes, it is often because of an approved post-approval change — you can reassure patients that the medicine is the same approved product.
- Understanding global registration explains why the same Indian-made medicine is sold in dozens of countries — each sale sits on a separate marketing authorization earned through a separate dossier.

India Context

- India is often called the "pharmacy of the world" because Indian companies supply a huge share of the world's generic medicines and vaccines. Global registration of Indian products — filing dossiers in the US, Europe, ASEAN, Africa, and other markets — is one of the largest employers of Indian pharmacy graduates.
- CDSCO is India's own drug authority for domestic approvals; for exports, Indian companies deal with each importing country's authority separately, using CTD/eCTD/ACTD dossiers as studied in Chapter 10.
- The Government of India supports pharma exports through trade and export promotion frameworks (as per the latest policies/notifications — confirm the current edition), and Indian RA professionals routinely manage DMFs, LOAs, and overseas supplements for hundreds of products.

Key Points

1. Global registration = getting marketing authorization country by country, each under that country's own rules.
2. General overseas procedure: study rules → prepare dossier (CTD/eCTD/ACTD) → appoint local agent if required → submit + fee → answer queries → inspection if required → authorization.
3. A post-approval change is any change to an already-approved product, process, or labelling.
4. Changes are classified by risk: major (high), moderate (medium), minor (low).
5. Major changes need a prior-approval supplement — permission BEFORE implementing.
6. Minor changes are handled by simple notification, often in periodic reports.
7. Rule of thumb: bigger risk → stricter control and earlier permission.
8. Every change must first pass the company's internal change-control system with supporting data proving the product is still equivalent.

Common Confusions

1. **"Once approved, can the company change anything freely?"** No. The approval covers the exact product and process filed. Changes must be reported through supplements/notifications based on risk.
2. **"Is a supplement the same as a new NDA/ANDA?"** No. A supplement is an addition to the ALREADY-approved application, not a fresh application.
3. **"Do all countries accept the same dossier?"** No. The CTD core (Modules 2–5) is common, but Module 1 and national requirements differ — each country reviews separately and gives its own authorization.
4. **"Are post-approval changes only about manufacturing?"** No. They also cover formulation, packaging, labelling, and administrative changes.
5. **"Minor change = no need to tell anyone?"** Wrong. Even minor changes must be notified to the authority through the defined route — "minor" means simple reporting, not silence.

Common Mistakes

1. Writing "a company can implement a major change and inform later" — major changes need PRIOR approval before implementation.
2. Confusing "supplement" with "notification" — supplement is the formal filing (needed for review/approval of significant changes); notification is the simpler information route for low-risk changes.
3. Saying "one global approval works everywhere" — there is no single worldwide approval; each country's authority grants its own marketing authorization.
4. Forgetting the local agent step — many countries require a local representative for foreign applicants (as per that country's rules).
5. Mixing up the risk order — remember: major > moderate > minor in both risk and regulatory strictness.

Mnemonics

- **"Study, Dossier, Submit, Answer, Inspect, Sell"** — the six beats of overseas registration: **S**tudy rules, **D**ossier, **S**ubmit, **A**nswer queries, **I**nspect, **S**ell.
- **Traffic lights for changes: R**ed = majo**R** (stop, approval first); **Y**ellow = moderate (caution, defined route); **G**reen = minor (go, just notify).
- **"Big change, big permission"** — the bigger the risk, the bigger the paperwork and the earlier the permission.
- **SUPPLEMENT = "SUPporting docuMENT for a change"** — an addition to the approved file.

Exam Summary

- **Global registration of Indian products:** country-by-country marketing authorization in overseas markets. Procedure: (1) study the target country's rules and dossier format; (2) check eligibility (generic vs new drug, patent status); (3) prepare the dossier in CTD/eCTD/ACTD with country-specific Module 1; (4) appoint a local agent if required; (5) submit with fee; (6) respond to queries; (7) undergo GMP inspection if required; (8) receive marketing authorization.
- **Post-approval changes:** any change to an approved product/process/labelling after NDA/ANDA approval. Classified by risk into major (high), moderate (medium), and minor (low).
- **Supplements:** formal filings added to the NDA/ANDA for changes needing review; major changes need prior-approval supplements (permission before implementing).
- **Notifications:** simpler information route for low-risk changes, sometimes via periodic reports.
- Core principle: the higher the risk to quality/safety/effectiveness, the stricter the control — bigger risk means earlier permission.
- All changes first pass through the company's internal change-control system with supporting data.

One-Minute Revision

Selling Indian medicines abroad = one authorization per country: study rules → dossier (CTD/eCTD/ACTD) → local agent → submit → answer queries → inspection → authorization. After approval, changes are risk-graded: major = red light (prior-approval supplement, permission first), moderate = yellow (defined route), minor = green (just notify). "Big change, big permission."

Questions

Short questions:

1 What is meant by "global registration" of a drug product?

2 List any four steps in registering an Indian drug product in an overseas market.

3 Why might a country require a local agent for a foreign applicant?

4 What is a post-approval change? Give two examples.

5 Name the three risk categories of post-approval changes.

6 What is a supplement in the context of NDA/ANDA?

7 What is a notification? When is it used?

8 Give one example each of a major change and a minor change.

9 What is change control?

10 Why can't a company implement a major change without prior approval?

Long questions:

1 Describe the general procedure for registration of Indian drug products in overseas markets, with a flowchart.

2 What are post-approval changes to NDA and ANDA? Classify them by risk with examples, and explain the reporting route for each category.

3 Explain the concepts of supplements and notifications. When is a prior-approval supplement required?

4 A company wants to change its API supplier after its ANDA is approved. Explain the complete process from the internal proposal to implementation, including risk classification and regulatory filing.

5 Distinguish between the generic registration route and the new-drug registration route for Indian products in overseas markets.

MCQs (with answer key):

1 "Global registration" of an Indian drug product means:

a) One approval valid in all countries b) Obtaining marketing authorization country by country in overseas markets c) Registration only with CDSCO d) Patent filing worldwide **Answer: b**

1 Which dossier formats are commonly used for overseas filings?

a) Only handwritten applications b) CTD / eCTD / ACTD, with country-specific Module 1 c) Only the company's internal format d) No dossier is needed abroad **Answer: b**

1 A post-approval change is:

a) A change made before filing the NDA b) Any change to an already-approved product, process, or labelling c) Only a price change d) A change of the company owner **Answer: b**

1 A change of API manufacturing process with significant impact is classified as:

a) Minor b) Moderate c) Major d) Administrative **Answer: c**

1 A major post-approval change requires:

a) No information to the authority b) A prior-approval supplement — permission before implementing c) Only an internal email d) A new patent **Answer: b**

1 A spelling correction in the patient leaflet is best classified as:

a) Major change b) Moderate change c) Minor change — handled by notification d) Not a change at all **Answer: c**

1 A supplement is:

a) A fresh NDA for a new drug b) A formal addition to the already-approved NDA/ANDA for a change c) A vitamin product d) An advertising brochure **Answer: b**

1 The guiding principle of post-approval change control is:

a) All changes need the same paperwork b) Higher risk → stricter control and earlier permission c) Minor changes need prior approval d) Changes need no data support **Answer: b**

Viva questions:

1 What is marketing authorization?

2 Name the steps of overseas registration in order.

3 What is the purpose of a local agent?

4 Define post-approval change in one sentence.

5 Give two examples of manufacturing-related post-approval changes.

6 What is the difference between a supplement and a notification?

7 Why do major changes need prior approval?

8 What is internal change control, and why does it come before regulatory filing?

Application-based questions:

1 An Indian generic company wants to sell its tablets in two foreign countries — one in Southeast Asia and one elsewhere. Explain how its dossier strategy would differ between the two, referencing CTD, eCTD, and ACTD from Chapter 10.

2 After ANDA approval, your company plans to (a) shift production to a new factory with a different tablet press, and (b) correct a typo on the carton. Classify each change, state the regulatory route for each, and explain what supporting work the company must do before filing.

3 A foreign authority sends a query asking for additional stability data during review of your company's dossier. Describe the next steps your regulatory affairs team would take.

4 New safety information about a rare side effect emerges for your approved product. What post-approval regulatory action is needed, and why is prompt action important for patients?

References

- Berry & Martin (The Pharmaceutical Regulatory Process)
- Gallin & Ognibene (Principles and Practice of Clinical Research)
- Guarino (New Drug Approval Process)
- Ng (Drugs: From Discovery to Approval)
- Pisano & Mantus (Textbook of FDA Regulatory Affairs)
- Weinberg (Guidebook for Drug Regulatory Submissions)

CHAPTER 12: Clinical Research Phases and Trial Documents

Learning Objectives

By the end of this chapter, you will be able to:

1 Define clinical research and explain why a new drug must be tested in phases.

2 State the objectives of clinical trial phases I, II, III, and IV in simple words.

3 Describe the subjects used in each phase (healthy volunteers vs. patients) and the design of each phase.

4 List the important documents of a clinical trial and explain the purpose of each.

5 Explain the contents of a trial protocol, a Case Report Form (CRF), and a Clinical Study Report (CSR).

6 Draw and explain the flow of clinical trial phases from the first human dose to post-marketing.

Definitions

- **Clinical research:** Research done in human beings to find out whether a new medicine is safe and whether it works. "Clinical" means "related to patients and medical care."
- **Clinical trial:** A planned experiment in which a new medicine (or vaccine, or medical treatment) is given to human subjects under carefully controlled conditions, to answer specific questions about safety and effect.
- **Investigational product:** The new medicine being tested in the trial. It is still under investigation and has not yet received marketing approval.
- **Subject (participant):** A human being who takes part in a clinical trial. A subject can be a healthy volunteer or a patient.
- **Healthy volunteer:** A person who has no disease and takes part in a trial, usually in Phase I, to help scientists understand how the drug behaves in the body.
- **Phase:** A stage of clinical testing. Each phase answers a different question and uses a different group and number of subjects.
- **Safety:** How harmless a drug is — whether it causes any unwanted effects when given to humans.
- **Efficacy:** How well a drug produces the desired effect, for example lowering blood pressure, in controlled trial conditions.
- **Effectiveness:** How well a drug works in real-life, everyday use (used more in Phase IV discussions).
- **Pharmacokinetics (PK):** What the body does to the drug — how the drug is absorbed, distributed, broken down, and removed from the body.
- **Pharmacodynamics (PD):** What the drug does to the body — the effect the drug produces.

- **Endpoint:** The specific result a trial measures to judge success, for example "reduction in blood sugar level" or "number of patients cured."
- **Protocol:** The written plan of a clinical trial. It describes what will be done, how, when, and by whom. It is like the rule book of the trial.
- **Case Report Form (CRF):** The form on which the data of each individual subject in a trial is recorded, for example age, dose given, blood test results, and side effects.
- **Investigator's Brochure (IB):** A document given to the trial doctor that contains all known information about the investigational product — earlier laboratory results, animal study results, and previous human data.
- **Clinical Study Report (CSR):** The final written report of a completed trial. It describes what was done, what was found, and what the results mean.
- **Randomization:** The process of assigning subjects to treatment groups by chance (like drawing lots), so that the groups are fair and comparable.
- **Blinding (masking):** Keeping the subject, the doctor, or both unaware of which treatment a subject is receiving, so that expectations do not influence the result.
- **Placebo:** A "dummy" treatment with no active medicine, used for comparison to see whether the new drug truly works.
- **Adverse event:** Any unwanted medical happening in a trial subject, whether or not it is related to the drug.
- **Multicentre trial:** A trial conducted at many hospitals or research centres at the same time.

Terminology Table

Term	Simple meaning	Remember it as
Clinical trial	A planned test of a new medicine in humans	"The exam of the drug"
Phase I	First test in humans — mainly safety	"Is it SAFE?"
Phase II	First test in patients — does it work?	"Does it WORK?"
Phase III	Large test — confirm it works and is safe	"PROVE it"
Phase IV	Test after approval — real-life use	"AFTER sale watch"
Protocol	The written plan/rule book of the trial	"Recipe of the trial"
CRF	Data form for each subject	"Report card of each volunteer"
IB	Information booklet about the drug for the doctor	"Drug's CV/biodata"
CSR	Final report of the whole trial	"Result book of the trial"
Endpoint	What the trial measures	"The target score"
Randomization	Assigning by chance	"Toss of a coin"
Blinding	Hiding who got the real drug	"Closed eyes test"
Placebo	Dummy medicine	"Sugar pill"

Term	Simple meaning	Remember it as
Healthy volunteer	A healthy person in the trial	"First brave tester"
Multicentre trial	Trial at many centres	"Many schools, one exam"

Simple Explanations

What is clinical research, and why is it needed?

Before a new drug can be sold in a pharmacy, it must be proven safe and effective in humans. Laboratory tests and animal tests (called **non-clinical studies**, which you studied in Unit II) can only tell us so much. Animals are not humans. A medicine that is safe in a rat may not be safe in a person.

Clinical research is the stage where the new drug is tested step by step in human beings. It is done in **phases** — small, careful steps — because giving an untested chemical to a large number of people at once would be dangerous. Each phase asks one main question:

- **Phase I — "Is it safe in humans?"**
- **Phase II — "Does it work in patients?"**
- **Phase III — "Does it really work and is it safe in a large group, compared with the current treatment?"**
- **Phase IV — "What happens when thousands of people use it in real life after it is sold?"**

Only if the answer at each step is good does the drug move to the next step.

Phase I: The first test in humans

- **Objective:** To find out whether the drug is safe in humans, what dose can be tolerated, and what the body does to the drug (pharmacokinetics).
- **Subjects:** Usually **healthy volunteers** — people with no disease. For very risky drugs (like cancer drugs), patients with the disease may be used instead, because it would not be fair to expose a healthy person to such a drug.
- **Number of subjects:** Small — typically a few dozen subjects, as described in standard textbooks.
- **Design:** The trial is usually done in one hospital or research unit where subjects can be watched closely. First, a very small single dose is given to a few subjects. If nothing harmful happens, the dose is slowly increased in new groups (**dose escalation**). Later, repeated doses are tested. Blood samples are taken to measure how much drug is in the blood over time.
- **Key point:** This phase looks for **side effects** and the **maximum tolerated dose**. It does not try to cure anyone.

Phase II: The first test in patients

- **Objective:** To find out whether the drug **works** in patients who have the disease, and to find the best dose.
- **Subjects:** A small group of **patients** suffering from the disease the drug is meant to treat.

- **Number of subjects:** Larger than Phase I — typically a few hundred subjects at most, as described in standard textbooks. Phase II is sometimes split into Phase IIa (early proof that the drug works) and Phase IIb (finding the best dose).
- **Design:** Patients are divided into groups. Some groups get different doses of the new drug; another group may get a placebo or the current standard treatment for comparison. The trial watches whether the disease improves and records side effects.
- **Key point:** This phase answers **"Does it work, and at what dose?"** Many drugs fail here because they are safe but simply do not cure the disease.

Phase III: The large confirmatory test

- **Objective:** To **confirm** that the drug works and is safe in a large group of patients, and to compare it with the current best treatment.
- **Subjects:** A large number of **patients** with the disease.
- **Number of subjects:** Large — typically hundreds to a few thousand, as described in standard textbooks.
- **Design:** This is usually a **randomized, controlled, multicentre trial**. Subjects are randomly assigned to groups (new drug vs. standard treatment or placebo), conducted at many hospitals and sometimes in many countries. Strict rules are followed, and results are compared scientifically.
- **Key point:** The data from Phase III is the main evidence used when the company applies for **permission to sell the drug** (marketing approval). If Phase III fails, years of work and money are lost.

Phase IV: After the drug is sold

- **Objective:** To watch the drug's safety and effect in **real-life use**, when thousands or lakhs of people use it for a long time.
- **Subjects:** The general public — ordinary patients using the drug as prescribed by their doctors.
- **Design:** These are **post-marketing studies**. They include long-term follow-up studies and special studies in groups that were not well studied earlier, such as children, elderly people, or pregnant women.
- **Key point:** Some rare side effects appear only when a very large number of people use the drug for a long time. Phase IV catches these. (You will study this monitoring in detail in Chapter 14 — pharmacovigilance.)

Classifications

1. Classification of clinical trial phases by purpose

1 **Phase I — Safety and pharmacokinetics** (first in humans; healthy volunteers)

2 **Phase II — Efficacy and dose finding** (small patient group; IIa = proof of effect, IIb = dose finding)

3 **Phase III — Confirmation** (large patient group; IIIa = before approval, IIIb = after approval but before the drug is widely sold)

4 **Phase IV — Post-marketing surveillance** (after approval; real-life use)

2. Classification of trial designs

- **By comparison:**
- **Controlled trial:** The new drug is compared with another group (placebo or standard treatment). Called "controlled" because the comparison group acts as a control.
- **Uncontrolled trial:** No comparison group; mainly used in early phases.
- **By knowledge of treatment (blinding):**
- **Open-label:** Everyone knows who gets the new drug.
- **Single-blind:** The subject does not know, but the doctor knows.
- **Double-blind:** Neither the subject nor the doctor knows — the most reliable design.
- **By assignment:**
- **Randomized trial:** Subjects are assigned to groups by chance.
- **Non-randomized trial:** Subjects are assigned by the doctor's choice or by order of joining.
- **By number of centres:**
- **Single-centre trial:** Done at one hospital.
- **Multicentre trial:** Done at many hospitals, sometimes in many countries.

Mechanisms / Processes

Process 1: The journey of a drug through the phases (the decision gate process)

1 **Non-clinical testing complete.** Laboratory and animal studies show the drug is promising and reasonably safe. (Studied in Unit II.)

2 **Permission to test in humans is obtained** from the regulatory authority, as per the latest rules/guidelines/notifications — confirm the current edition.

3 **Phase I begins.** A very small dose is given to a few healthy volunteers under close watch.

- *Decision gate:* If serious harm appears, the drug is stopped. If safe, move to Phase II.

1 **Phase II begins.** The drug is given to a small group of patients at different doses.

- *Decision gate:* If the drug does not work, the drug is stopped. If it works, move to Phase III.

1 **Phase III begins.** Large randomized controlled trials at many centres compare the drug with standard treatment.

- *Decision gate:* If results are good, the company applies for **marketing approval**. If results are poor, the drug is stopped.

1 **Marketing approval granted.** The drug can now be sold.

2 **Phase IV begins.** The drug is watched in real-life use for long-term and rare effects.

Process 2: What happens inside a single Phase III trial (step by step)

1 **Protocol is written** — the full plan of the trial.

2 **Approvals are taken** — from the ethics committee and the regulatory authority, as per the latest rules/guidelines/notifications — confirm the current edition. (Details in Chapter 13.)

3 **Centres and investigators are selected** — qualified hospitals and doctors join the trial.

4 **Subjects are enrolled** — patients who match the trial's rules (called **inclusion and exclusion criteria**) are invited, informed, and their written consent is taken.

5 **Subjects are randomized** into groups — for example, Group A gets the new drug, Group B gets the standard treatment.

6 **Treatment and follow-up** — subjects take the treatment and visit the hospital regularly. At each visit, the doctor records health information on the Case Report Form.

7 **Monitoring** — trial monitors check that the trial is running as per the protocol. (Details in Chapter 13.)

8 **Data analysis** — at the end, statisticians compare the groups: Did more patients improve on the new drug? Were side effects acceptable?

9 **Clinical Study Report is written** — the final report of the trial.

Textual Diagrams / Flowcharts

Diagram 1: Flow of clinical trial phases




Diagram 2: The decision gate — what happens after each phase





Diagram 3: Documents created during a trial (in order of use)



Infographic Concept

INFOGRAPHIC CONCEPT: A four-step climbing staircase labelled "From Lab to Pharmacy Shelf." Step 1 (Phase I): a small group of healthy volunteers under a magnifying glass, caption "Is it safe?" Step 2 (Phase II): a small group of patients with a medicine bottle, caption "Does it work?" Step 3 (Phase III): a crowd of patients across multiple hospital buildings, caption "Prove it in thousands." Between the steps, red "STOP" gates show that the drug can be dropped at any step. At the top of the stairs, a pharmacy shelf with the approved medicine; an eye symbol above it labelled Phase IV, caption "Keep watching after sale." Use green for "go" and red for "stop" at each gate.

Tables

Table 1: Comparison of clinical trial phases

Feature	Phase I	Phase II	Phase III	Phase IV
Main question	Is it safe in humans?	Does it work in patients?	Does it really work and is it safe, compared with current treatment?	What happens in real-life long-term use?
Subjects	Healthy volunteers (patients for risky drugs)	Small group of patients	Large group of patients	General public using the drug
Typical size	Small (few dozen)	Moderate (up to a few hundred)	Large (hundreds to thousands)	Very large (thousands to lakhs)
Main purpose	Safety, tolerated dose, pharmacokinetics	Efficacy, best dose	Confirm efficacy and safety	Detect rare/long-term effects
Design	Dose escalation, close monitoring, often one centre	Dose comparison, some controls	Randomized, controlled, multicentre	Post-marketing studies, long follow-up
Decision after	Go to Phase II if safe	Go to Phase III if it works	Apply for marketing approval if confirmed	Update safety information as needed

Table 2: Key clinical trial documents

Document	Prepared by	Main contents	Purpose
Investigator's Brochure (IB)	Sponsor (the company)	All known data on the drug: lab results, animal studies, earlier human data, safety information	To inform the trial doctor so they can judge risks and treat subjects safely
Trial protocol	Sponsor with experts	Objective, design, subject rules (inclusion/exclusion), dose, tests, endpoints, safety reporting, statistics plan	The rule book — everyone follows the same plan
Informed Consent Form	Sponsor/investigator	Purpose of trial, procedures, risks, benefits, rights of the subject, voluntary participation	Written proof that the subject agreed after understanding (details in Chapter 13)
Case Report Form (CRF)	Sponsor (design); filled by investigator's team	Each subject's data: identity code, medical history, doses, test results, side effects	Clean, uniform data collection for every subject
Clinical Study Report (CSR)	Sponsor	What was planned, what was done, results, analysis, conclusions	Final record of the trial; used in approval applications

Table 3: Trial design terms at a glance

Design term	What it means	Why it is used
Randomized	Groups formed by chance	Makes groups fair and comparable
Controlled	Compared against placebo or standard treatment	Shows the drug's true effect
Blind (single/double)	Subject/doctor do not know the treatment	Removes bias from expectations
Multicentre	Many hospitals take part	Faster enrolment; results apply to more people

Design term	What it means	Why it is used
Crossover	Subjects switch treatments midway	Each subject acts as their own comparison

Examples

Example 1 — A new blood pressure drug's journey: A company develops "Drug X" for high blood pressure. In Phase I, 40 healthy volunteers receive increasing single doses; the drug is tolerated and blood samples show how long it stays in the body. In Phase II, 150 patients with high blood pressure receive different doses for 8 weeks; the 10 mg dose lowers blood pressure well with mild headache as the main side effect. In Phase III, 2,000 patients at 30 hospitals are randomized to Drug X or the current standard drug; Drug X lowers blood pressure equally well with fewer side effects. The company applies for marketing approval. In Phase IV, after launch, the drug is used by lakhs of people, and long-term data confirm its safety.

Example 2 — What a protocol contains (simplified): Title: "A trial of Drug X in patients with high blood pressure." Objective: "To compare the blood-pressure-lowering effect of Drug X 10 mg with standard treatment over 12 weeks." Subjects: "Adults aged 30–65 with high blood pressure; pregnant women excluded." Design: "Randomized, double-blind, multicentre." Endpoints: "Change in blood pressure at 12 weeks; number of side effects."

Example 3 — What a CRF records for one subject: Subject code: HTN-0143. Age: 52. Dose given: Drug X 10 mg daily. Visit 1 blood pressure: 160/100. Visit 4 blood pressure: 132/84. Side effects: mild headache on day 3, gone by day 5. The subject's name is never written on the CRF — only the code, to protect privacy.

Analogies

Analogy 1 — Testing a new recipe. Phase I is like tasting a new dish yourself first to check it is not poisonous. Phase II is like serving it to your family to see if they like it. Phase III is like serving it at a big wedding to hundreds of guests and comparing it with the usual dish. Phase IV is like opening a restaurant and watching customer reviews for years.

Analogy 2 — School examinations. Phase I is the practice test (check the basics). Phase II is the class test (does the student really know the subject?). Phase III is the board examination (the big final proof, checked strictly). Phase IV is the student's performance in real life after passing (does the knowledge actually help in a job?).

Analogy 3 — Trial documents as a journey file. The Investigator's Brochure is the traveller's guidebook about the destination (the drug). The protocol is the tour itinerary that everyone must follow. The CRF is the daily diary of each traveller. The Clinical Study Report is the final travel report of the whole trip.

Pharmacy Relevance

- **Pharmacists work in clinical research.** A pharmacist may work as a clinical research coordinator, trial pharmacist, or in the sponsor company, handling the investigational product — receiving, storing, dispensing, and accounting for every tablet used in the trial.
- **Counselling trial subjects.** Pharmacists explain to subjects how to take the trial medicine, what side effects to watch for, and what to do if a dose is missed.
- **Drug information.** The pharmacist is often the person who understands the Investigator's Brochure and protocol best at the trial site and answers the doctor's questions about the drug.

- **Career path.** Knowledge of trial phases and documents is the foundation for jobs in clinical research organizations (CROs), pharmaceutical companies, and hospital research departments.

India Context

- Clinical trials in India require prior permission from the national regulatory authority, as per the latest rules/guidelines/notifications — confirm the current edition. The approval process and trial conduct must follow Good Clinical Practice (GCP) guidelines, which are linked with Schedule Y (studied in Unit III).
- Ethics committee approval is mandatory before any trial begins in India (details in Chapter 13).
- The trial documents described in this chapter — protocol, Investigator's Brochure, Case Report Form, and Clinical Study Report — are the same documents expected in Indian regulatory submissions, as per the latest guidelines — confirm the current edition.

Key Points

1. Clinical research tests a new drug in humans in four phases: I (safety), II (efficacy), III (confirmation), IV (post-marketing).
2. Phase I uses healthy volunteers; Phases II and III use patients; Phase IV covers the general public.
3. Each phase has a decision gate — the drug moves forward only if the results are good.
4. Phase III data is the main evidence for marketing approval.
5. The protocol is the rule book of the trial; the CRF records each subject's data; the IB informs the doctor; the CSR is the final report.
6. Randomized, controlled, blinded, multicentre designs give the most reliable results.

Common Confusions

- **Efficacy vs. effectiveness:** Efficacy is how well the drug works in the controlled conditions of a trial; effectiveness is how well it works in real life. Phase II/III measure efficacy; Phase IV looks at effectiveness.
- **Adverse event vs. side effect:** An adverse event is any unwanted medical happening during the trial, whether or not the drug caused it. A side effect (adverse drug reaction) is an unwanted effect suspected to be caused by the drug.
- **Phase II vs. Phase III:** Both use patients, but Phase II is small and exploratory (does it work? what dose?), while Phase III is large and confirmatory (prove it works, compared with standard treatment).
- **IB vs. protocol:** The Investigator's Brochure describes the *drug* (what is known about it); the protocol describes the *trial* (what will be done).
- **CRF vs. CSR:** The CRF records data of *one subject*; the CSR is the final report of the *whole trial*.

Common Mistakes

1 Saying "Phase I tests whether the drug works" — wrong; Phase I mainly tests safety, not efficacy.

2 Saying "healthy volunteers are used in all phases" — wrong; only Phase I routinely uses healthy volunteers (patients are used in Phases II and III).

3 Mixing up the order — writing "Phase III before Phase II." The order is always I → II → III → approval → IV.

4 Calling the protocol "the final report" — the protocol is written *before* the trial; the Clinical Study Report is written *after*.

5 Writing that blinding means "the subject is blindfolded" — blinding means hiding *which treatment* was given, not covering the eyes.

Mnemonics

- **Phase questions — "S-E-C-W" (think "seek"):**
- **S** = Phase I: Is it **S**afe?
- **E** = Phase II: Is it **E**ffective?
- **C** = Phase III: **C**onfirm it works.
- **W** = Phase IV: **W**atch after sale.
- **Trial documents in order — "B-P-C-R" (think "beeper"):**
- **B** = Investigator's **B**rochure (about the drug)
- **P** = **P**rotocol (the plan)
- **C** = **C**ase Report Form (subject data)
- **R** = Clinical Study **R**eport (final report)
- **Best trial design — "R-C-B-M": R**andomized, **C**ontrolled, **B**linded, **M**ulticentre = most reliable.

Exam Summary

Clinical research is human testing of a new drug, done in phases after non-clinical studies. Phase I (first in humans, healthy volunteers, small group) tests safety, tolerated dose, and pharmacokinetics. Phase II (small patient group) tests whether the drug works and finds the best dose. Phase III (large, randomized, controlled, multicentre patient trial) confirms efficacy and safety versus standard treatment and provides the main evidence for marketing approval. Phase IV is post-marketing surveillance in real-life use, detecting rare and long-term effects. Key trial documents: the Investigator's Brochure (drug information for the doctor), the protocol (the trial's rule book), the Informed Consent Form (subject's written agreement), the Case Report Form (each subject's data), and the Clinical Study Report (the final report). Reliable designs are randomized, controlled, blinded, and multicentre.

One-Minute Revision

- Four phases: I = Safe? (healthy volunteers) → II = Works? (small patient group) → III = Prove it (large, multicentre) → IV = Watch after sale.

- Decision gate after each phase: only good results move forward.
- Documents: IB (drug info) → Protocol (plan) → Consent (permission) → CRF (data) → CSR (final report).
- Best design: randomized, controlled, blinded, multicentre.

Questions

Short Questions

1 Define clinical trial and clinical research.

2 What is the main objective of Phase I clinical trials?

3 Why are healthy volunteers used in Phase I?

4 What is the difference between Phase II and Phase III trials?

5 Define protocol, CRF, IB, and CSR in one line each.

6 What is randomization? Why is it done?

7 What is a placebo, and why is it used?

8 What is meant by a "decision gate" between trial phases?

9 Define endpoint with one example.

10 What is a multicentre trial?

Long Questions

1 Describe the objectives, subjects, and design of clinical trial phases I, II, III, and IV with a neat flow diagram.

2 Explain the important documents of a clinical trial. Describe the contents and purpose of the protocol and the Case Report Form.

3 Write a detailed note on trial designs: randomized, controlled, blinded, and multicentre trials.

4 Trace the journey of a new drug from non-clinical studies through all clinical phases to marketing approval, explaining the decision taken after each phase.

MCQs (with Answer Key)

1 The main objective of Phase I clinical trials is:

a) To confirm efficacy in a large population b) To test safety and tolerated dose in humans for the first time c) To compare with standard treatment d) To monitor the drug after marketing

1 Phase I trials are usually conducted in:

a) A large group of patients b) Healthy volunteers c) The general public d) Animals

1 The phase that provides the main evidence for marketing approval is:

a) Phase I b) Phase II c) Phase III d) Phase IV

1 Phase IV trials are conducted:

a) Before Phase III b) After the drug is approved and marketed c) Only in animals d) Only in healthy volunteers

1 The "rule book" of a clinical trial is the:

a) Case Report Form b) Protocol c) Investigator's Brochure d) Clinical Study Report

1 Data of each individual subject is recorded in the:

a) Protocol b) Investigator's Brochure c) Case Report Form d) Informed Consent Form

1 The final report of a completed trial is called the:

a) Clinical Study Report b) Case Report Form c) Trial protocol d) Subject diary

1 In a double-blind trial:

a) Only the subject is unaware of the treatment b) Only the doctor is unaware of the treatment c) Neither the subject nor the doctor knows the treatment given d) Everyone knows the treatment

1 Randomization in clinical trials is done to:

a) Reduce the cost of the trial b) Make treatment groups fair and comparable c) Increase the dose d) Avoid ethics approval

1 A placebo is:

a) A new active drug b) A dummy treatment with no active medicine c) A side effect d) A trial document

Answer Key: 1-b, 2-b, 3-c, 4-b, 5-b, 6-c, 7-a, 8-c, 9-b, 10-b

Viva Questions

1 Name the four phases of clinical trials in order.

2 What is tested in Phase II?

3 Who prepares the Investigator's Brochure?

4 What is the difference between a CRF and a CSR?

5 What does "blinded" mean in a trial?

6 Why is Phase III usually multicentre?

Application-Based Questions

1 A company wants to test a new diabetes drug in 2,500 patients at 40 hospitals, comparing it with the current standard drug, with neither patients nor doctors knowing who gets which treatment. Identify the phase and the design features.

2 During a trial, the investigator wants to change the dose for all subjects because she feels it is too low. Using your knowledge of trial documents, explain why she must not do this on her own and what document governs such changes.

3 A trial subject develops a fever during the study. The fever may be due to the drug or due to a viral infection. As a trial pharmacist, how would you record this, and in which document?

References

- Gallin and Ognibene, Principles and Practice of Clinical Research
- Ng, Drugs: From Discovery to Approval
- Guarino, New Drug Approval Process
- Berry and Martin, The Pharmaceutical Regulatory Process

CHAPTER 13: IRB/IEC, Informed Consent and GCP Obligations

Learning Objectives

By the end of this chapter, you will be able to:

1 Define Institutional Review Board (IRB) and Independent Ethics Committee (IEC).

2 Describe the formation (composition) and functions of an IRB/IEC.

3 Explain the informed consent process and its documentation, step by step.

4 State the Good Clinical Practice (GCP) obligations of the investigator, the sponsor, and the monitor.

5 Describe how clinical trials are managed and monitored.

6 Explain the difference between monitoring, audit, and inspection.

Definitions

- **Institutional Review Board (IRB) / Independent Ethics Committee (IEC):** A group of medical, scientific, and non-scientific people that reviews a clinical trial plan to protect the rights, safety, and well-being of the human subjects. IRB and IEC are two names for the same kind of body — "IRB" is the term commonly used in the USA, and "IEC" (or Ethics Committee) is the term commonly used in India and in international guidelines. Both do the same job.
- **Ethics:** Moral principles about right and wrong. In clinical research, ethics means treating trial subjects with respect, fairness, and honesty.
- **Informed consent:** The process by which a subject voluntarily agrees to take part in a trial after being told, in understandable language, about the trial's purpose, procedures, risks, benefits, and their rights.

- **Informed Consent Form (ICF):** The written document that records the information given to the subject and carries the subject's (and witness's, if needed) signature as proof of agreement.
- **Good Clinical Practice (GCP):** An international standard for designing, conducting, recording, and reporting clinical trials. Following GCP protects the subjects and makes the trial data trustworthy.
- **Investigator:** The doctor (or qualified professional) who is responsible for conducting the trial at a trial site and for the care of the subjects there. The **principal investigator** is the leader at that site.
- **Sponsor:** The person, company, or organization that takes responsibility for starting, managing, and financing the clinical trial (usually the pharmaceutical company).
- **Monitor:** The person appointed by the sponsor who regularly checks that the trial is being conducted as per the protocol, GCP, and regulations. Monitoring is like quality checking during the trial.
- **Audit:** An independent, systematic examination of the trial — its documents, data, and conduct — to check whether everything was done correctly. An audit is like an internal inspection.
- **Inspection:** An official examination of the trial by a **regulatory authority** (for example, CDSCO in India or US FDA in the USA).
- **Source document:** The original record where trial data is first written, for example the hospital case sheet, laboratory report, or the subject's diary.
- **Essential documents:** The documents that prove the trial was conducted properly and the data is reliable — for example, the approved protocol, ethics committee approvals, consent forms, and CRFs.
- **Vulnerable subjects:** People who need extra protection because they may not be fully free to decide, such as children, mentally ill persons, or very poor or illiterate persons.
- **LAR (Legally Acceptable Representative):** A person legally allowed to give consent on behalf of a subject who cannot consent personally, such as a parent for a child.

Terminology Table

Term	Simple meaning	Remember it as
IRB / IEC	Committee that protects trial subjects	"Guardian committee"
Informed consent	Agreeing after full understanding	"Permission after full story"
GCP	International quality standard for trials	"Rule book for good trials"
Investigator	The trial doctor at the site	"Captain of the site"
Sponsor	The company funding and owning the trial	"Owner of the trial"
Monitor	Sponsor's checker during the trial	"Quality inspector"
Audit	Independent check of the trial	"Internal exam"
Inspection	Official check by the regulator	"Government raid"
Source document	Original record of data	"The original notebook"
Essential documents	Proof the trial was done right	"Evidence file"
Vulnerable subject	Needs extra protection	"Handle with extra care"
LAR	Person who consents for another	"Guardian signer"

Simple Explanations

Why do we need an IRB/IEC?

Imagine a company wants to test a new drug on people. The company wants the trial to succeed — that is its business interest. But who protects the people in the trial? Who checks that the trial plan is fair, the risks are acceptable, and nobody is being used or harmed?

That is the job of the **IRB/IEC** — an independent committee that stands **between the company and the subjects**, like a referee in a match. No trial can start until this committee reviews the protocol and says "approved." The committee keeps watching the trial while it runs and can stop it if subjects are at risk.

How is an IRB/IEC formed?

An IRB/IEC is formed as a group of **different kinds of people**, so that no single viewpoint dominates:

- **Medical/scientific members** — doctors and scientists who understand the medicine and the trial design.
- **Non-scientific members** — people from other fields who look at the trial with common sense.
- **A layperson** — an ordinary person from the community who represents the subjects' point of view.
- **A legal expert** — someone who understands the law and the subjects' legal rights.
- **A social scientist or ethicist** — someone who understands social and ethical issues.
- The committee should include both men and women, and members should be **independent** — they should not have a personal interest in the trial's success.

The exact composition and registration requirements are given in the latest rules/guidelines/notifications — confirm the current edition.

What does the IRB/IEC do? (Functions)

1. **Reviews the protocol** before the trial starts — is the science sound? Are the risks acceptable compared with the possible benefits?
2. **Reviews the informed consent form** — is it written in simple language the subject can understand?
3. **Reviews the Investigator's Brochure** and subject recruitment methods — how will subjects be found and invited?
4. **Gives written approval** before the trial begins — no approval, no trial.
5. **Reviews the trial while it runs** — at least once a year, and whenever there are major changes or safety problems.
6. **Reviews amendments** — if the protocol must be changed, the committee must approve the change first (except in an emergency to protect a subject).
7. **Can suspend or stop the trial** if subjects' safety is at risk.

The informed consent process — step by step

Informed consent is not just a signature on a paper. It is a **process** — a conversation. The steps are:

1 **Information:** The investigator (or trained team member) explains the trial to the subject in simple, local language — no medical jargon. The subject must be told:

- the purpose of the trial and why they are invited;
- what will be done to them (procedures, visits, tests);
- the possible risks and discomforts;
- the possible benefits (if any);
- alternative treatments available outside the trial;
- that participation is **voluntary** — they can refuse or withdraw at any time without any loss of medical care;
- that their personal information will be kept confidential;
- whom to contact if they have questions or problems.

1 **Understanding:** The subject is given time to think and ask questions. For illiterate subjects, the information is read out in the presence of an impartial witness.

2 **Voluntary decision:** The subject decides freely, without pressure or unfair inducement.

3 **Documentation:** The subject signs and dates the Informed Consent Form. The person who explained the trial also signs. A copy is given to the subject.

4 **Continuing consent:** If new safety information appears during the trial, subjects must be informed again, and the consent form is updated.

GCP obligations — who must do what?

Good Clinical Practice (GCP) divides responsibilities clearly among three parties:

Obligations of the investigator (the trial doctor):

- Conduct the trial exactly as per the approved protocol.
- Protect the rights, safety, and well-being of subjects — this is the first duty, above everything else.
- Obtain informed consent properly before any trial procedure.
- Ensure subjects get proper medical care for any trial-related problem.
- Record data accurately in the CRF and keep source documents.
- Report serious safety events to the sponsor and the ethics committee promptly.
- Allow monitoring, audits, and inspections, and give access to records.

Obligations of the sponsor (the company):

- Take overall responsibility for the trial — its initiation, management, and financing.
- Select qualified investigators and provide them with the protocol and the Investigator's Brochure.
- Ensure the investigational product is properly manufactured, labelled, stored, and accounted for.

- Appoint monitors and ensure the trial is monitored.
- Set up systems for safety reporting and for handling the trial data.
- Ensure the trial follows the protocol, GCP, and applicable regulations.
- Take insurance/indemnity cover for trial subjects, as required by the latest rules — confirm the current edition.

Obligations of the monitor (the sponsor's checker):

- Visit trial sites regularly and check that subjects' rights and safety are protected.
- Verify that the data recorded in CRFs matches the source documents (this is called **source data verification**).
- Check that the investigational product is stored and dispensed correctly and that records match.
- Confirm that informed consent was properly obtained from every subject.
- Report findings to the sponsor after each visit.

Management and monitoring of clinical trials

Trial management means running the trial in an organized way: planning timelines, training the site staff, supplying the investigational product, collecting data, and keeping all essential documents safe and complete.

Monitoring is the continuous quality check during the trial. The monitor:

1. makes a **pre-trial visit** to check that the site is suitable;
2. makes an **initiation visit** to train the site team on the protocol;
3. makes **routine visits** during the trial to check consent, data, drug records, and safety reporting;
4. makes a **close-out visit** at the end to collect remaining documents and confirm records are complete.

Audit vs. inspection (monitoring's bigger brothers):

- **Monitoring** = done by the sponsor's own monitor, during the trial, routinely.
- **Audit** = done by independent auditors (often hired by the sponsor), to systematically check quality.
- **Inspection** = done by the **regulatory authority** (government), which has legal power and can take action.

Classifications

1. Types of ethics review bodies

- **Institutional Review Board (IRB):** Term commonly used in the USA; usually attached to an institution.
- **Independent Ethics Committee (IEC):** Term commonly used in India and international guidelines; must be independent of the sponsor and investigator.

2. Types of ethics committee review

- **Initial review:** Full review of the protocol before the trial starts.
- **Continuing review:** Periodic review (at least yearly) while the trial is running.
- **Amendment review:** Review of proposed changes to the protocol or consent form.
- **Expedited review:** A faster, limited review for minor changes or minimal-risk matters, done by fewer members as permitted by the latest guidelines — confirm the current edition.

3. Elements of a valid informed consent

1 Information (full disclosure)

2 Understanding (comprehension)

3 Voluntariness (free choice)

4 Documentation (signed form)

4. Levels of trial oversight

1 **Monitoring** — by sponsor, routine, during the trial

2 **Audit** — independent, systematic, quality check

3 **Inspection** — by regulatory authority, legal power

Mechanisms / Processes

Process 1: How a trial gets ethics approval (step by step)

1 The sponsor/investigator prepares the **protocol, Investigator's Brochure, consent form, and subject recruitment material**.

2 These documents are submitted to the **IRB/IEC**.

3 The committee meets and reviews: Is the science valid? Are risks acceptable? Is the consent form understandable? Are subjects protected?

4 The committee gives one of three decisions: **approved**, **approved with modifications**, or **rejected**.

5 Only after written approval can subject enrolment begin.

6 During the trial, the investigator sends **periodic reports** and reports any serious safety events to the committee.

7 Any change to the protocol needs fresh committee approval before it is applied.

Process 2: The informed consent conversation (what actually happens at the hospital)

1 The doctor identifies a patient who matches the trial's rules.

2 In a private, unhurried conversation (in the patient's own language), the doctor explains the trial using the approved information sheet.

3 The patient is encouraged to ask questions and to discuss with family.

4 If the patient agrees, both the patient and the doctor sign and date the consent form; the patient receives a copy.

5 Only **after** consent is signed does any trial procedure (like a trial blood test) begin.

6 If important new safety information appears later, the patient is informed again and signs an updated form.

Textual Diagrams / Flowcharts

Diagram 1: Position of the IRB/IEC — the protector between company and subject




Diagram 2: Informed consent process flow





Diagram 3: Levels of trial oversight



Infographic Concept

INFOGRAPHIC CONCEPT: A shield-shaped infographic titled "Three Pillars of Trial Protection." Pillar 1: a committee table with diverse people (doctor, scientist, layperson, legal expert) labelled "IRB/IEC — the guardian committee." Pillar 2: a doctor handing a document to a patient with a speech bubble "You decide freely" labelled "Informed Consent — permission after full story." Pillar 3: a three-level pyramid labelled "GCP Oversight" with Monitor at the base ("sponsor's routine check"), Audit in the middle ("independent quality check"), and Inspection at the top ("regulator's official check"). The shield's motto at the bottom: "Subject safety first — always."

Tables

Table 1: IRB vs. IEC

Feature	IRB (Institutional Review Board)	IEC (Independent Ethics Committee)
Term used in	Commonly in the USA	Commonly in India and international guidelines
Attachment	Usually attached to an institution (hospital/university)	May be institutional or fully independent
Core job	Same	Same
Core job (detail)	Protect rights, safety, well-being of subjects; review and approve trials	Protect rights, safety, well-being of subjects; review and approve trials

Takeaway: Different names, same job — the guardian committee of the trial.

Table 2: Formation — who sits on the committee and why

Member type	Why they are needed
Medical/scientific members	To judge the science and medical risks
Non-scientific members	To apply common sense and community values
Layperson	To represent the ordinary subject's viewpoint
Legal expert	To protect legal rights
Social scientist/ethicist	To judge ethical and social issues
Women members	To ensure women's perspectives are included

Table 3: GCP obligations at a glance — investigator, sponsor, monitor

Area	Investigator	Sponsor	Monitor
First duty	Protect subjects' rights, safety, well-being	Overall responsibility for the trial	Check that the trial follows protocol and GCP
Documents	Follow the approved protocol; record data accurately	Provide protocol and Investigator's Brochure	Verify CRF data against source documents
Consent	Obtain proper informed consent	Ensure consent procedures are in place	Confirm consent was obtained from every subject
Product	Use the investigational product only as per protocol	Manufacture, label, supply, and account for the product	Check storage, dispensing, and records
Safety	Treat trial-related problems; report serious events promptly	Set up safety reporting systems	Check that safety events were reported
Oversight	Allow monitoring, audits, inspections	Appoint monitors; ensure monitoring happens	Report visit findings to the sponsor

Table 4: Monitoring vs. audit vs. inspection

Feature	Monitoring	Audit	Inspection
Done by	Sponsor's monitor	Independent auditors	Regulatory authority
When	Routinely during the trial	Periodically, as planned	When the regulator decides
Purpose	Day-to-day quality check	Systematic quality verification	Official legal verification
Power	Reports to sponsor	Reports findings	Can take regulatory action

Examples

Example 1 — Ethics committee in action: A company submits a trial protocol for a new painkiller to the ethics committee of a hospital. The committee finds that the consent form is written in difficult English that most patients will not understand. It approves the trial **only after** the consent form is rewritten in simple local language. This is the committee doing its job — protecting subjects before the trial starts.

Example 2 — A proper consent conversation: Mrs. Sharma, aged 55, is invited to join a diabetes drug trial. The doctor explains in Hindi: what the trial is for, that she will visit the hospital 6 times, that possible side effects include nausea, that she may instead continue her current medicine outside the trial, and that she can leave the trial at any time without affecting her treatment. She asks questions, takes the form home to discuss with her family, returns after two days, and signs. She receives a signed copy. This is valid informed consent.

Example 3 — The monitor's visit: During a routine visit, the monitor checks Subject No. 23's CRF, which says "blood pressure 130/80." The monitor opens the hospital case sheet (the source document) and finds "blood pressure 138/86." The monitor points out this mismatch and asks the site team to correct the CRF and be more careful. This is **source data verification**.

Example 4 — When the committee stops a trial: During a trial, several subjects develop an unexpected serious liver problem. The investigator reports this to the ethics committee. The committee reviews the safety data and **suspends** new enrolment until the problem is understood. Subject safety comes before the company's plans.

Analogies

Analogy 1 — The referee in a match. The sponsor is like a team that wants to win; the subjects are like the players who could get hurt. The IRB/IEC is the **referee** — independent, with the power to stop the game if the rules are broken or a player is in danger.

Analogy 2 — Consent as a train ticket with full information. Informed consent is like buying a train ticket after the booking clerk tells you the full journey — the route, the stops, the possible delays, the cost, and that you can cancel and get a refund. You would never board a train blindfolded; a subject should never join a trial without full information.

Analogy 3 — Oversight as school checking. Monitoring is the **class teacher** checking homework daily. Audit is the **principal** doing a surprise round. Inspection is the **board examiner** arriving with legal authority. All three check the same school, but at different levels.

Analogy 4 — GCP as traffic rules. GCP is like traffic rules for clinical trials. The investigator is the driver, the sponsor owns the transport company, and the monitor is the traffic inspector. Everyone must follow the same rules so that nobody gets hurt and everyone reaches safely.

Pharmacy Relevance

- **Pharmacists on ethics committees.** A qualified pharmacist can serve as a member of an ethics committee, contributing knowledge of medicines, drug interactions, and safe use.
- **Pharmacists as trial staff.** In hospital trials, the pharmacist often handles the investigational product and counsels subjects — so the pharmacist must understand consent and GCP duties.

- **Protecting subjects is a pharmacist's ethic too.** The pharmacy profession's core value — patient safety first — is exactly what IRB/IEC and GCP demand. Learning this chapter strengthens your professional identity.
- **Career link.** Roles like clinical research coordinator, trial monitor, and regulatory affairs executive all require working knowledge of ethics committees, consent, and GCP.

India Context

- In India, every clinical trial must be approved by a registered Ethics Committee before it starts, as per the latest rules/guidelines/notifications — confirm the current edition. Ethics committees in India are required to be registered with the national regulatory authority.
- Informed consent in India must be taken in a language the subject understands, and the process for illiterate and vulnerable subjects follows the latest guidelines — confirm the current edition.
- GCP guidelines applicable in India are linked with Schedule Y (studied in Unit III); trial conduct, monitoring, and inspections in India follow these, as per the latest rules/guidelines/notifications — confirm the current edition.

Key Points

1 IRB and IEC are two names for the same guardian committee that protects trial subjects.

2 The committee must have diverse members — medical, scientific, non-scientific, layperson, legal expert — and be independent.

3 No trial starts without the committee's written approval; the committee also reviews the trial while it runs and can stop it.

4 Informed consent is a process: information → understanding → voluntary decision → documentation → continuing consent.

5 GCP divides duties: the investigator conducts and protects subjects; the sponsor owns and manages; the monitor checks.

6 Monitoring (sponsor, routine) → audit (independent, systematic) → inspection (regulator, legal power) are the three levels of oversight.

Common Confusions

- **IRB vs. IEC:** Not two different jobs — just two names (USA vs. India/international) for the same guardian committee.
- **Investigator vs. sponsor vs. monitor:** The investigator is the trial doctor at the site; the sponsor is the company that owns the trial; the monitor is the sponsor's person who checks the site. Three different roles — do not mix them.
- **Audit vs. inspection:** An audit is an independent quality check (often arranged by the sponsor); an inspection is an official check by the government regulator with legal power.

- **Consent form vs. consent process:** The signed form is only the *proof*; the real consent is the *conversation* — information, understanding, and free decision.
- **Source document vs. CRF:** The source document is where data is first recorded (hospital file, lab report); the CRF is the trial form where the data is copied/entered for the study.

Common Mistakes

1 Writing "the sponsor conducts the trial at the hospital" — wrong; the **investigator** conducts it at the site, the sponsor manages and funds it.

2 Saying "consent is just taking a signature" — wrong; a signature without information and understanding is not valid consent.

3 Saying "the ethics committee approves once and its job is over" — wrong; it reviews the trial continuously and can suspend it.

4 Mixing up monitor and auditor — the monitor works for the sponsor and visits routinely; the auditor is independent and checks systematically.

5 Forgetting vulnerable subjects — children, mentally ill, and illiterate persons need extra protection, not standard treatment.

Mnemonics

- **Committee members — "M-N-L-L-S" (think "mnlls"):**
- **M**edical/scientific, **N**on-scientific, **L**ayperson, **L**egal expert, **S**ocial scientist.
- **Consent process — "I-U-V-D-C" (think "I, you, we decide carefully"):**
- **I**nformation → **U**nderstanding → **V**oluntary decision → **D**ocumentation → **C**ontinuing consent.
- **Oversight levels — "M-A-I" (think "my eye watches"):**
- **M**onitoring (sponsor) → **A**udit (independent) → **I**nspection (regulator).
- **Who does what — "I-S-M": I**nvestigator conducts, **S**ponsor owns, **M**onitor checks.

Exam Summary

The IRB/IEC (Institutional Review Board / Independent Ethics Committee) is the independent guardian committee that protects the rights, safety, and well-being of trial subjects. It is formed of diverse members — medical, scientific, non-scientific, a layperson, a legal expert, and a social scientist — and must be independent. Its functions: review and approve the protocol, consent form, and recruitment methods before the trial; give written approval; review the trial periodically and review amendments; and suspend or stop the trial if safety is at risk. Informed consent is a process — information in understandable language, checking understanding, free voluntary decision, signed documentation (with a witness for illiterate subjects and a copy for the subject), and re-consent if new safety information appears. Under GCP, the investigator conducts the trial per protocol and protects subjects; the sponsor takes overall responsibility, supplies the product and brochure, and appoints monitors; the monitor routinely verifies consent, data against source documents, drug records, and safety reporting. Trial oversight has three

levels: monitoring (sponsor), audit (independent), and inspection (regulatory authority).

One-Minute Revision

- IRB/IEC = guardian committee; diverse, independent; approves before, watches during, can stop.
- Consent = I-U-V-D-C: Information → Understanding → Voluntary → Documentation → Continuing.
- GCP duties: Investigator conducts, Sponsor owns, Monitor checks.
- Oversight: Monitoring (sponsor) → Audit (independent) → Inspection (regulator).

Questions

Short Questions

1 What is an IRB/IEC? Why is it needed?

2 Name any four types of members of an ethics committee.

3 List three functions of an IRB/IEC.

4 What are the four elements of valid informed consent?

5 What is GCP?

6 State two obligations of the investigator under GCP.

7 State two obligations of the sponsor under GCP.

8 What does a monitor verify during a site visit?

9 Differentiate between audit and inspection.

10 Who is a vulnerable subject? Give two examples.

Long Questions

1 Describe the formation and functions of an Institutional Review Board / Independent Ethics Committee.

2 Explain the informed consent process and its documentation step by step, including special care for illiterate and vulnerable subjects.

3 Describe the GCP obligations of the investigator, sponsor, and monitor with a comparison table.

4 Write a note on the management and monitoring of clinical trials, explaining monitoring, audit, and inspection.

MCQs (with Answer Key)

1 The main job of an IRB/IEC is to:

a) Fund the clinical trial b) Protect the rights, safety, and well-being of trial subjects c) Manufacture the investigational product d) Analyse the trial statistics

1 Which of the following should be a member of an ethics committee?

a) Only doctors b) Only company employees c) A mix including a layperson and a legal expert d) Only statisticians

1 A clinical trial can begin:

a) As soon as the sponsor is ready b) Only after written approval from the IRB/IEC c) After Phase III is complete d) Without any approval

1 Valid informed consent requires:

a) Only the subject's signature b) Information, understanding, voluntary decision, and documentation c) Payment to the subject d) Approval from the sponsor only

1 If a subject is illiterate, consent should be taken:

a) Without any witness b) By reading the information aloud in the presence of an impartial witness c) Only from the doctor d) Over the telephone

1 Under GCP, the person who conducts the trial at the site is the:

a) Sponsor b) Monitor c) Investigator d) Auditor

1 Source data verification during monitoring means:

a) Checking CRF entries against the original source documents b) Signing the consent form c) Manufacturing the drug d) Writing the final report

1 An inspection of a clinical trial is conducted by:

a) The sponsor's monitor b) An independent auditor hired by the sponsor c) The regulatory authority d) The subject

1 Which of the following is an obligation of the sponsor?

a) Treating the subjects daily b) Appointing monitors and ensuring the trial is monitored c) Signing consent on behalf of subjects d) Conducting surgery

1 Continuing review by the ethics committee means:

a) One-time approval before the trial b) Periodic review of the trial while it is running c) Review after the drug is marketed d) Review of animal studies only

Answer Key: 1-b, 2-c, 3-b, 4-b, 5-b, 6-c, 7-a, 8-c, 9-b, 10-b

Viva Questions

1 Expand IRB and IEC.

2 Can a trial start without ethics committee approval?

3 What is the difference between a monitor and an auditor?

4 What is a source document? Give one example.

5 Who gives consent for a child participating in a trial?

6 What should a subject be told about withdrawing from a trial?

Application-Based Questions

1 An investigator wants to start enrolling patients in a trial using a protocol that the ethics committee approved "with modifications." The modifications have not yet been made. Advise the investigator.

2 A subject signed the consent form but later says she did not understand that blood would be drawn five times. As a member of the trial team, what went wrong, and how should proper consent have been handled?

3 During a monitoring visit, you find that the investigational product stock register does not match the number of tablets dispensed according to the CRFs. Whose obligation is this, and what should the monitor do?

References

- Gallin and Ognibene, Principles and Practice of Clinical Research
- Berry and Martin, The Pharmaceutical Regulatory Process
- Pisano and Mantus, Textbook of FDA Regulatory Affairs

CHAPTER 14: Pharmacovigilance During Clinical Trials and Post-Marketing

Learning Objectives

By the end of this chapter, you will be able to:

1 Define pharmacovigilance and explain why it is needed.

2 Differentiate between an adverse event (AE) and an adverse drug reaction (ADR).

3 Describe how safety is monitored during clinical trials.

4 Describe how safety is monitored after marketing (post-marketing surveillance).

5 Explain the steps of ADR reporting and signal detection in simple words.

6 Explain the concept of a Risk Management Plan (RMP) and a Periodic Safety Update (PSUR/PBRER).

7 Describe the role of regulatory bodies in post-marketing surveillance.

Definitions

- **Pharmacovigilance:** The science of detecting, assessing, understanding, and preventing unwanted effects of medicines. "Pharmaco" means medicine, and "vigilance" means watchfulness. So pharmacovigilance = "watchfulness over medicines."

- **Adverse event (AE):** Any unwanted medical happening in a person who has taken a medicine — for example, a headache, a rash, or a hospital admission. The medicine may or may not have caused it.
- **Adverse drug reaction (ADR):** An unwanted effect that is **suspected to be caused** by the medicine at its normal dose.
- **Side effect:** A commonly used word for an unwanted effect of a medicine; in regulatory language, a side effect that is suspected to be caused by the drug is an ADR.
- **Serious adverse event (SAE):** An adverse event that results in death, is life-threatening, needs hospital admission (or makes a hospital stay longer), causes lasting disability, or causes a birth defect.
- **SUSAR:** Suspected Unexpected Serious Adverse Reaction — a serious reaction that is suspected to be caused by the trial drug and was **not expected** (not listed in the known safety information). SUSARs must be reported quickly during clinical trials.
- **Signal:** New information suggesting that a medicine may cause a previously unknown harmful effect, or that a known effect is happening more often or more seriously than before. A signal is a "warning bell," not yet a proof.
- **Signal detection:** The process of finding signals from safety data — like a smoke detector sensing smoke before a fire is confirmed.
- **Causality assessment:** The scientific judgement of whether the medicine actually caused the unwanted event, or whether something else caused it.
- **Spontaneous reporting:** Voluntary reporting of suspected ADRs by doctors, pharmacists, nurses, or patients to the authorities — the backbone of post-marketing safety monitoring.
- **Risk Management Plan (RMP):** A document that describes the known and possible risks of a medicine and explains what will be done to watch for them and reduce them.
- **Periodic Safety Update Report (PSUR) / Periodic Benefit-Risk Evaluation Report (PBRER):** A report prepared by the company at regular intervals after marketing, summarizing all new worldwide safety information about the medicine and judging whether its benefits still outweigh its risks.
- **Post-marketing surveillance:** Watching a medicine's safety after it is approved and sold to the public — mainly through Phase IV studies and spontaneous ADR reporting.
- **Benefit-risk balance:** The judgement that a medicine's benefits (curing disease) are greater than its risks (side effects). A medicine stays on the market only while this balance is favourable.
- **Regulatory action:** Steps a regulatory authority can take when a safety problem is found — for example, updating the product label, issuing a warning, restricting use, recalling batches, or withdrawing the medicine.

Terminology Table

Term	Simple meaning	Remember it as
Pharmacovigilance	Watchfulness over medicines	"Medicine watchdog"
AE	Any unwanted happening after taking a drug	"Anything bad that happened"
ADR	Unwanted effect suspected to be caused by the drug	"Drug is the suspect"

Term	Simple meaning	Remember it as
SAE	AE that is serious (death, hospital, disability)	"Red-alert event"
SUSAR	Serious + unexpected + suspected drug reaction in a trial	"Trial emergency signal"
Signal	New warning bell about a possible harm	"Smoke before fire"
Signal detection	Finding warning bells in data	"Smoke detector"
Causality assessment	Judging whether the drug really caused it	"Detective work"
Spontaneous reporting	Voluntary ADR reports by health workers	"Citizen complaints box"
RMP	Plan describing risks and how to manage them	"Safety battle plan"
PSUR/PBRER	Company's regular safety summary report	"Safety report card"
Post-marketing surveillance	Safety watch after the drug is sold	"After-sale watch"
Benefit-risk balance	Benefits bigger than risks?	"Weighing scale"

Simple Explanations

Why do we need pharmacovigilance?

Clinical trials (Chapter 12) test a drug in a few thousand people at most, for a limited time, under controlled conditions. But after approval, **lakhs of people** use the drug — including children, elderly people, pregnant women, and people taking many other medicines — for **many years**. Some harmful effects are so rare (say, 1 in 50,000 users) that they can never be seen in a trial of 3,000 people. Some effects appear only after years of use.

Pharmacovigilance is the system that keeps watching the medicine **for its entire life on the market**. Without it, a harmful drug could keep injuring people silently for years.

Safety monitoring during clinical trials

During trials, safety is watched very closely because the drug is still experimental:

1. **Every adverse event is recorded.** Whatever bad happens to a subject — headache, fever, accident — is written in the CRF.
2. **Serious events are reported fast.** If a serious adverse event occurs, the investigator informs the sponsor and the ethics committee promptly.
3. **SUSARs are reported urgently.** A serious, unexpected reaction suspected to be caused by the trial drug is reported to regulators within strict timelines, as per the latest rules/guidelines/notifications — confirm the current edition.
4. **Ongoing safety review.** The sponsor's safety team continuously reviews incoming safety data. For some trials, an independent safety committee watches unblinded safety data and can recommend stopping the trial.

Safety monitoring after marketing (post-marketing surveillance)

After approval, the main tools are:

1. **Spontaneous ADR reporting:** Doctors, pharmacists, nurses, and patients voluntarily report suspected ADRs to the national system. This is the most important source of new safety information worldwide.
2. **Phase IV studies:** Planned studies after marketing that follow large groups of users (Chapter 12).
3. **Signal detection:** Experts analyse the collected reports to find signals — for example, "many reports of liver injury with Drug X, more than expected."
4. **Signal evaluation and causality assessment:** The signal is investigated — is the drug really the cause?
5. **Regulatory action:** If the signal is confirmed, the regulator acts — label update, warning letter, restricted use, recall, or withdrawal.

The concept of a Risk Management Plan (RMP)

An RMP is the company's **safety battle plan** for a medicine. In simple words, it answers three questions:

1. **What are the risks?** — the safety specification: known risks, possible risks, and missing information (for example, "not studied in children").
2. **How will we watch for them?** — the pharmacovigilance plan: routine reporting plus any special studies.
3. **How will we reduce them?** — risk minimization measures: for example, special warnings in the label, educational material for doctors, or restricted distribution.

The concept of the Periodic Safety Update (PSUR/PBRER)

After marketing, the company must regularly prepare a **safety report card** on its medicine — the PSUR (also called PBRER in current international practice). It contains:

- all new safety information collected worldwide during the period (trial data, spontaneous reports, published literature);
- an analysis of signals;
- an updated judgement of the **benefit-risk balance** — do the benefits still outweigh the risks?

The report is submitted to regulatory authorities at defined intervals, as per the latest rules/guidelines/notifications — confirm the current edition. If the balance becomes unfavourable, action follows.

Role of regulatory bodies in post-marketing surveillance

Regulatory authorities (such as CDSCO in India, US FDA in the USA, and EMA in Europe) play these roles:

1. **Collect safety data** — they run or oversee the national ADR reporting system.
2. **Detect and evaluate signals** — their experts analyse reports for new risks.
3. **Order label changes and warnings** — so doctors and patients know the new risk.
4. **Restrict use** — for example, "not to be used in children" if a risk appears in children.
5. **Recall or withdraw** — batches or the whole product can be removed from the market if the risk is unacceptable.

6 **Communicate** — they issue safety alerts to health professionals and the public.

Classifications

1. Types of safety information

- **Adverse event (AE):** any unwanted happening (cause unknown or unrelated).
- **Adverse drug reaction (ADR):** unwanted effect suspected to be caused by the drug.
- **Serious adverse event (SAE):** AE with serious outcomes (death, life-threatening, hospitalization, disability, birth defect).
- **SUSAR:** serious + unexpected + suspected to be caused by the trial drug.

2. Sources of post-marketing safety data

1 Spontaneous ADR reports (doctors, pharmacists, nurses, patients)

2 Phase IV / post-marketing studies

3 Published medical literature

4 Reports from other countries' regulators

3. Possible regulatory actions (in increasing order of seriousness)

1 Update the product label (add the new warning)

2 Issue a safety communication / warning letter to health professionals

3 Restrict the use (for example, only in hospitals, or not in certain patients)

4 Recall affected batches

5 Suspend or withdraw the marketing approval

4. Parts of a Risk Management Plan

1 **Safety specification** — what are the risks and what is not yet known

2 **Pharmacovigilance plan** — how the risks will be watched

3 **Risk minimization measures** — how the risks will be reduced

Mechanisms / Processes

Process 1: The ADR reporting chain (spontaneous reporting)

1 A patient takes a medicine and develops a suspected unwanted effect.

2 The doctor/pharmacist/nurse records the details: patient details, medicine name, dose, dates, description of the reaction, outcome.

3 The report is sent to the national pharmacovigilance system (in India, through the national programme's reporting network, as per the latest guidelines — confirm the current edition).

4 The report enters a database with thousands of similar reports.

5 Experts assess causality — was the drug the likely cause?

Process 2: Signal detection and management (step by step)

1 **Collect:** ADR reports accumulate in the database.

2 **Detect:** Analysts notice a pattern — for example, an unusually high number of liver injury reports with Drug X. This pattern is a **signal** (a warning bell, not proof).

3 **Validate:** Check whether the signal is real or due to errors, duplicates, or coincidence.

4 **Evaluate:** Detailed scientific review — study the cases, look at trial data and literature, assess causality.

5 **Decide:** Is the risk confirmed? How serious is it? What is the benefit-risk balance now?

6 **Act:** Regulatory action — label update, warning, restriction, recall, or withdrawal.

7 **Communicate:** Inform doctors, pharmacists, and the public.

Process 3: How a PSUR is built and used

1 During the reporting period, the company collects **all** worldwide safety data on the medicine.

2 The safety team analyses the data, reviews signals, and updates the benefit-risk judgement.

3 The PSUR/PBRER document is written.

4 It is submitted to regulatory authorities at the required intervals.

5 Regulators review it and may ask for more data or take action.

Textual Diagrams / Flowcharts

Diagram 1: Safety watch across the drug's life




Diagram 2: From a patient's complaint to regulatory action




Diagram 3: The Risk Management Plan — three questions

```
┌──────────────────────────────────────┐
│         RISK MANAGEMENT PLAN         │
│         (the safety battle plan)     │
├──────────────────────────────────────┤
│ 1. WHAT are the risks?               │
│    Safety specification: known risks,│
│    possible risks, missing information│
├──────────────────────────────────────┤
│ 2. HOW will we watch for them?       │
│    Pharmacovigilance plan: routine   │
│    reporting + special studies       │
├──────────────────────────────────────┤
│ 3. HOW will we reduce them?          │
│    Risk minimization: label warnings,│
│    doctor education, restricted supply│
└──────────────────────────────────────┘
```

Infographic Concept

INFOGRAPHIC CONCEPT: A "medicine watchdog" theme — a large watchful eye over a medicine strip, titled "Pharmacovigilance: Watching Medicines for Life." Around it, four panels: Panel 1 "During Trials" shows a hospital with a clipboard (every event recorded, SUSARs reported fast). Panel 2 "After Marketing" shows doctors, pharmacists, and patients dropping report cards into a collection box (spontaneous reporting). Panel 3 "Signal Detection" shows a smoke detector with report cards rising like smoke, caption "Find the warning bell." Panel 4 "Action" shows a regulator's hand holding a stamp with options: label update, warning, recall, withdrawal. A balance scale at the bottom labelled "Benefit vs. Risk — must stay favourable."

Tables

Table 1: AE vs. ADR vs. SAE vs. SUSAR

Term	Meaning	Example	Where it matters most
Adverse event (AE)	Any unwanted happening after taking the drug (cause may be unrelated)	A trial subject catches the flu during the study	Recorded in every trial
Adverse drug reaction (ADR)	Unwanted effect suspected to be caused by the drug	Rash appearing two days after starting Drug X	Post-marketing reporting
Serious adverse event (SAE)	AE with serious outcome: death, life-threatening, hospitalization, disability, birth defect	A subject is hospitalized with severe breathing difficulty	Fast reporting in trials
SUSAR	SAE + unexpected + suspected to be caused by the trial drug	Sudden liver failure never seen before with the trial drug	Urgent reporting to regulators during trials

Table 2: Safety monitoring — during trials vs. after marketing

Feature	During clinical trials	After marketing (post-marketing)
Population	Few thousand selected subjects	Lakhs of general users
Duration	Months to a few years	Many years (lifetime of the drug)

Feature	During clinical trials	After marketing (post-marketing)
Main data source	CRFs, planned safety tests	Spontaneous ADR reports, Phase IV studies
Reporting speed	SAEs/SUSARs reported fast/urgently	Reports collected continuously
Who watches	Investigator, sponsor safety team, ethics committee	Company, regulators, health professionals, patients
Main goal	Protect subjects; decide if the drug can be approved	Detect rare/long-term risks; keep benefit-risk favourable

Table 3: What a PSUR/PBRER contains

Section	Contents in simple words
Worldwide safety data	All new ADRs, trial safety results, and literature reports in the period
Signal analysis	Which warning bells appeared and what was found on investigation
Benefit-risk evaluation	Updated judgement: do benefits still outweigh risks?
Actions taken	Label changes, warnings, or restrictions already made
Conclusion	Overall safety statement and proposals for further action

Table 4: Regulatory actions in post-marketing surveillance

Action	When it is used	Example in simple words
Label update	A new risk is confirmed but the drug is still useful	Add "may cause dizziness" to the package insert
Safety communication	Doctors and public must be warned quickly	Letter to all doctors about the new risk
Restricted use	Risk is high in a certain group	"Not for use in children below 12 years"
Recall	Specific batches are defective or unsafe	"Return all tablets of batch no. 123"
Withdrawal	Risks outweigh benefits overall	The medicine is removed from the market

Examples

Example 1 — AE vs. ADR: During a trial of a new allergy drug, Subject 12 develops a headache. The headache could be due to the drug, or due to lack of sleep. It is recorded as an **adverse event**. After review, the doctor notes that headaches started in many subjects within hours of taking the drug and stopped when the drug was stopped — now it is suspected to be an **adverse drug reaction**.

Example 2 — A signal leading to action: After marketing, a national database receives an unusually high number of reports of muscle pain with Drug Y — far more than expected. This pattern is a **signal**. Experts investigate, confirm the link, and the regulator orders a **label update**: "Drug Y may cause muscle pain; consult your doctor." Doctors are informed through a safety communication.

Example 3 — Spontaneous reporting by a pharmacist: A community pharmacist notices that three different patients developed the same unusual skin rash after starting the same newly launched antibiotic. The pharmacist reports all three cases to the national pharmacovigilance system. These reports join the

database where signal detection may later find a pattern. One careful pharmacist's reports can protect thousands.

Example 4 — RMP in action: A new medicine is known to harm unborn babies (from animal studies). Its Risk Management Plan states this as a known risk, plans a pregnancy registry study to watch for it (pharmacovigilance plan), and requires the label to carry a strong warning plus educational material for doctors (risk minimization). The drug stays available for patients who need it, with the risk controlled.

Analogies

Analogy 1 — The car recall system. Pharmacovigilance is like a car company's safety system. Cars are tested before sale (trials), but after lakhs of cars are on the road, owners report problems (spontaneous reporting). If many owners report brake failure (signal), the company investigates and recalls the cars (regulatory action). The car stays on the road only while it is safe.

Analogy 2 — Signal as a smoke detector. A signal is like a smoke detector's beep. The beep does not prove there is a fire — it might be burnt toast — but you must check. Signal detection beeps when ADR patterns look unusual; evaluation checks whether there is a real fire (a true drug risk).

Analogy 3 — PSUR as a school report card. The PSUR is the medicine's periodic report card. Just as a student's report card summarizes performance each term, the PSUR summarizes the medicine's safety performance each period, with a final judgement: "still safe to continue" (benefits outweigh risks) or "needs action."

Analogy 4 — RMP as a battle plan. Before a cricket captain walks onto the field, she studies the opponent's strengths (risks), plans field placements (watching for risks), and prepares bowling changes (reducing risks). The Risk Management Plan does the same for a medicine's safety.

Pharmacy Relevance

- **Pharmacists are frontline ADR reporters.** The community or hospital pharmacist is often the first health professional to hear about a suspected ADR from a patient. Reporting it is a professional duty.
- **Patient counselling prevents ADRs.** Explaining the correct dose, timing, food interactions, and warning signs helps patients use medicines safely — this is pharmacovigilance in daily practice.
- **The pharmacist's eye for signals.** A pharmacist who notices the same complaint from multiple patients on the same drug may be spotting an early signal.
- **Career link.** Pharmacovigilance is a major career field for pharmacists — drug safety associate, signal detection scientist, and QPPV (qualified person for pharmacovigilance) support roles in pharmaceutical companies and CROs all build on this chapter.

India Context

- India has a national pharmacovigilance programme that collects ADR reports from across the country through a network of centres, as per the latest guidelines/notifications — confirm the current edition. Doctors, pharmacists, nurses, and patients can all contribute reports.
- Marketing authorization holders (companies selling medicines in India) are expected to monitor the safety of their products and submit periodic safety updates to the national regulatory authority, as per the latest rules/guidelines/notifications — confirm the current edition.

- CDSCO, India's national drug regulator, takes post-marketing regulatory actions — label changes, warnings, recalls, and withdrawals — based on safety evaluations, as per the latest rules — confirm the current edition.

Key Points

1. Pharmacovigilance = detecting, assessing, understanding, and preventing unwanted effects of medicines.
2. AE = any unwanted happening; ADR = suspected to be caused by the drug; SAE = serious outcome; SUSAR = serious + unexpected + suspected in a trial.
3. During trials: record every AE, report SAEs fast, report SUSARs urgently.
4. After marketing: spontaneous reporting + Phase IV studies → signal detection → evaluation → regulatory action.
5. A signal is a warning bell, not proof — it must be validated and evaluated.
6. RMP answers: what are the risks, how will we watch, how will we reduce them.
7. PSUR/PBRER is the company's regular safety report card judging the benefit-risk balance.
8. Regulators act on confirmed risks: label update, warning, restriction, recall, or withdrawal.

Common Confusions

- **AE vs. ADR:** Every ADR starts as an AE, but not every AE is an ADR. AE = "something bad happened"; ADR = "the drug is suspected to have caused it."
- **Signal vs. proof:** A signal is only a suspicion from patterns in data. Proof comes after proper evaluation. Never say "the signal proved the drug is harmful."
- **PSUR vs. RMP:** The RMP is the *plan* (what are the risks and what will we do); the PSUR is the *report* (what safety data came in and what it means).
- **Phase IV vs. pharmacovigilance:** Phase IV studies are *one tool* of post-marketing surveillance; pharmacovigilance is the *whole system* (spontaneous reporting + studies + signal detection + action).
- **Recall vs. withdrawal:** A recall removes specific batches from the market; a withdrawal removes the product's approval entirely.

Common Mistakes

1. Writing "ADR and side effect are completely different" — in regulatory language, a side effect suspected to be caused by the drug is reported and handled as an ADR.
2. Saying "only doctors can report ADRs" — wrong; pharmacists, nurses, and patients can also report through spontaneous reporting systems.
3. Saying "a signal means the drug is proven harmful" — wrong; a signal is a hypothesis that must be evaluated.

4 Forgetting trial safety — writing only about post-marketing and missing SUSAR reporting and ethics committee safety reporting during trials.

5 Mixing up PSUR and CSR — the CSR is the final report of *one trial*; the PSUR is the periodic safety summary of a *marketed medicine*.

Mnemonics

- **PV definition — "DAUP" (think "daup" = watch): D**etect, **A**ssess, **U**nderstand, **P**revent unwanted effects.
- **Serious event criteria — "D-L-H-D-B": D**eath, **L**ife-threatening, **H**ospitalization, **D**isability, **B**irth defect.
- **Signal process — "C-D-V-E-D-A-C" (think "see the deck"):**
- **C**ollect → **D**etect → **V**alidate → **E**valuate → **D**ecide → **A**ct → **C**ommunicate.
- **RMP three questions — "W-H-H": W**hat are the risks? **H**ow will we watch? **H**ow will we reduce?
- **Regulatory actions ladder — "L-W-R-R-W" (think "lwrw"): L**abel update → **W**arning → **R**estriction → **R**ecall → **W**ithdrawal.

Exam Summary

Pharmacovigilance is the science of detecting, assessing, understanding, and preventing unwanted effects of medicines. An adverse event (AE) is any unwanted happening after drug intake; an adverse drug reaction (ADR) is an unwanted effect suspected to be caused by the drug; a serious adverse event (SAE) has serious outcomes (death, life-threatening, hospitalization, disability, birth defect); a SUSAR is a serious, unexpected, suspected reaction in a trial. During clinical trials, every AE is recorded, SAEs are reported fast to the sponsor and ethics committee, and SUSARs are reported urgently to regulators. After marketing, safety is monitored through spontaneous ADR reporting by health professionals and patients, Phase IV studies, published literature, and international data. Signal detection finds patterns (warning bells) in the data; signals are validated and evaluated through causality assessment; confirmed risks lead to regulatory action — label update, safety communication, restricted use, recall, or withdrawal. The Risk Management Plan describes a medicine's risks, how they will be watched (pharmacovigilance plan), and how they will be reduced (risk minimization). The Periodic Safety Update Report (PSUR/PBRER) is the company's regular worldwide safety summary judging whether benefits still outweigh risks. Regulatory bodies collect safety data, detect and evaluate signals, and take and communicate regulatory actions.

One-Minute Revision

- PV = Detect, Assess, Understand, Prevent (DAUP).
- AE (anything bad) → ADR (drug suspected) → SAE (serious: D-L-H-D-B) → SUSAR (trial emergency).
- Trials: record all, report SAEs fast, SUSARs urgently.
- Post-marketing: spontaneous reports → signal → evaluate → act (L-W-R-R-W).
- RMP = risks + watch plan + reduce plan; PSUR = regular safety report card.

Questions

Short Questions

1 Define pharmacovigilance.

2 Differentiate between AE and ADR with one example each.

3 What is a serious adverse event? List its criteria.

4 What is a SUSAR?

5 What is a signal in pharmacovigilance?

6 What is spontaneous reporting?

7 What are the three parts of a Risk Management Plan?

8 What is a PSUR/PBRER?

9 Name three regulatory actions in post-marketing surveillance.

10 What is benefit-risk balance?

Long Questions

1 Define pharmacovigilance. Describe safety monitoring during clinical trials and after marketing, highlighting the differences.

2 Explain the process of ADR reporting and signal detection with a neat flow diagram.

3 Write a note on the concept of the Risk Management Plan and the Periodic Safety Update Report.

4 Describe the role of regulatory bodies in post-marketing surveillance, with examples of regulatory actions.

MCQs (with Answer Key)

1 Pharmacovigilance is the science of:

a) Manufacturing medicines b) Detecting, assessing, understanding, and preventing unwanted effects of medicines c) Marketing medicines d) Testing medicines in animals

1 An adverse drug reaction (ADR) is:

a) Any unwanted happening after taking a drug, whatever the cause b) An unwanted effect suspected to be caused by the drug c) A serious event only d) An event seen only in trials

1 Which of the following is a criterion for a serious adverse event?

a) Mild headache b) Hospitalization c) Common cold d) Missed dose

1 SUSAR stands for:

a) Suspected Unexpected Serious Adverse Reaction b) Safe Use of Standard Approved Remedies c) Serious Unreported Side-effect Assessment Report d) Systematic Update of Safety and Reactions

1 A signal in pharmacovigilance is:

a) Proof that a drug is harmful b) New information suggesting a possible harmful effect — a warning bell c) A marketing signal d) A trial protocol amendment

1 The backbone of post-marketing safety monitoring is:

a) Spontaneous ADR reporting b) Animal testing c) Advertising d) Price control

1 Causality assessment means:

a) Counting the number of tablets b) Judging whether the drug actually caused the unwanted event c) Writing the product label d) Approving the drug

1 A Risk Management Plan does NOT include:

a) Safety specification b) Pharmacovigilance plan c) Risk minimization measures d) The drug's manufacturing formula

1 The PSUR/PBRER is prepared by:

a) The patient b) The marketing authorization holder (company) c) The pharmacist alone d) The ethics committee

1 If a confirmed risk is found after marketing but the drug is still useful, the regulator may first:

a) Withdraw the drug immediately b) Update the product label with a warning c) Stop all clinical trials worldwide d) Ban all medicines

Answer Key: 1-b, 2-b, 3-b, 4-a, 5-b, 6-a, 7-b, 8-d, 9-b, 10-b

Viva Questions

1 Expand PV, ADR, SAE, SUSAR, RMP, PSUR.

2 Give one difference between a clinical trial CSR and a PSUR.

3 Who can report a suspected ADR?

4 What is the first regulatory action usually taken when a new risk is confirmed?

5 What is the difference between a recall and a withdrawal?

6 Why can rare side effects be missed in clinical trials?

Application-Based Questions

1 A pharmacist notices that four patients on a newly launched blood pressure drug developed a persistent dry cough within a week of starting it. What should the pharmacist do, and how does this fit into the pharmacovigilance system?

2 During a clinical trial, a subject develops sudden severe liver damage that was never seen with the drug before. Identify what this event is called and describe the reporting responsibilities.

3 A regulator confirms that a marketed painkiller increases the risk of heart attack in elderly patients, but the drug is the only effective option for severe pain in younger patients. Suggest a proportionate regulatory response using the actions ladder.

References

- Berry and Martin, The Pharmaceutical Regulatory Process
- Pisano and Mantus, Textbook of FDA Regulatory Affairs
- Guarino, New Drug Approval Process
- Weinberg, Guidebook for Drug Regulatory Submissions